|
|
???tair.name??? >
???browser.page.title.author???
|
"maerten a"???jsp.browse.items-by-author.description???
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
| 國立臺灣大學 |
2015 |
Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm plus ) non-small cell lung cancer (NSCLC)
|
Passaro, A.; Yang, J. C.; Ahn, M.; Dickgreber, N. J.; Halmos, B.; Hirsh, V.; Hochmair, M. J.; Levy, B. P.; de Marinis, F.; Mok, T.; O'Byrne, K.; Okamoto, I.; Schuler, M.; Sebastian, M.; Shah, R.; Tan, E.; Yamamoto, N.; Maerten, A.; Wind, S.; Carbone, D. P.; 楊志新 |
| 國立臺灣大學 |
2015 |
Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)
|
Wu, Y. -L.; Sequist, L. V.; Geater, S. L.; Orlov, S.; Lee, K. H.; Tsai, C. -M.; Kato, T.; Kiura, K.; Barrios, C. H.; Schuler, M.; Hirsh, V.; Yamamoto, N.; O'Byrne, K.; Mok, T.; Massey, D.; Maerten, A.; Yang, J. C. -H.; 楊志新 |
Showing items 1-2 of 2 (1 Page(s) Totally)
1
View [10|25|50] records per page
|
